Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
(2025) In QJM - Monthly Journal of the Association of Physicians 118(1). p.3-4
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/834f54e1-4dba-4cb3-a031-2f6418b8303f
- author
- Hakariya, Hayase ; Ozaki, Akihiko ; Mulinari, Shai LU ; Moriarty, Frank and Tanimoto, Tetsuya
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- in
- QJM - Monthly Journal of the Association of Physicians
- volume
- 118
- issue
- 1
- pages
- 3 - 4
- publisher
- Oxford University Press
- external identifiers
-
- pmid:38867701
- scopus:85198074596
- ISSN
- 0033-5622
- DOI
- 10.1093/qjmed/hcae115
- language
- English
- LU publication?
- yes
- id
- 834f54e1-4dba-4cb3-a031-2f6418b8303f
- date added to LUP
- 2024-06-13 16:09:40
- date last changed
- 2025-09-29 15:07:21
@article{834f54e1-4dba-4cb3-a031-2f6418b8303f, author = {{Hakariya, Hayase and Ozaki, Akihiko and Mulinari, Shai and Moriarty, Frank and Tanimoto, Tetsuya}}, issn = {{0033-5622}}, language = {{eng}}, number = {{1}}, pages = {{3--4}}, publisher = {{Oxford University Press}}, series = {{QJM - Monthly Journal of the Association of Physicians}}, title = {{Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval}}, url = {{http://dx.doi.org/10.1093/qjmed/hcae115}}, doi = {{10.1093/qjmed/hcae115}}, volume = {{118}}, year = {{2025}}, }